CRD 4730
Alternative Names: CRD-4730Latest Information Update: 06 Dec 2023
At a glance
- Originator Cardurion Pharmaceuticals
- Class Antiarrhythmics
- Mechanism of Action Calcium-calmodulin-dependent protein kinase type 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Polymorphic catecholergic ventricular tachycardia
Most Recent Events
- 07 Nov 2023 Phase-II clinical trials in Polymorphic catecholergic ventricular tachycardia in USA (PO) (NCT06005428)
- 28 Aug 2023 Phase-I clinical trials in Polymorphic catecholergic ventricular tachycardia in Unknown location (PO), prior to August 2023 (Cardurion pharmaceuticals pipeline, August 2023)
- 22 Aug 2023 Cardurion Pharmaceuticals plans a phase II trial for Polymorphic catecholergic ventricular tachycardia in September 2023 (PO) (NCT06005428)